Vaxart Announces Trading on OTCQX Best Market
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, announced its transition to trading on the OTCQX Best Market effective July 8, 2025. The company received a delisting notice from Nasdaq and has requested a hearing before the Nasdaq Hearings Panel, with its stock currently suspended from Nasdaq trading.
CEO Steven Lo emphasized the company's commitment to advancing their proprietary oral pill vaccine development while considering all options regarding their stock listing. Shareholders are not required to take any action regarding this trading transition.
Vaxart (OTCQX: VXRT), un'azienda biotecnologica in fase clinica che sviluppa vaccini ricombinanti orali in forma di pillola, ha annunciato il passaggio alla quotazione sul mercato OTCQX Best Market a partire dall'8 luglio 2025. La società ha ricevuto una notifica di esclusione da Nasdaq e ha richiesto un'audizione presso il Nasdaq Hearings Panel; attualmente il suo titolo è sospeso dalle negoziazioni su Nasdaq.
Il CEO Steven Lo ha sottolineato l'impegno dell'azienda nel portare avanti lo sviluppo dei propri vaccini orali in pillola, valutando tutte le opzioni relative alla quotazione azionaria. Gli azionisti non devono intraprendere alcuna azione in relazione a questa transizione di negoziazione.
Vaxart (OTCQX: VXRT), una empresa biotecnológica en etapa clínica que desarrolla vacunas recombinantes orales en forma de pastilla, anunció su transición a cotizar en el mercado OTCQX Best Market a partir del 8 de julio de 2025. La compañía recibió un aviso de exclusión de Nasdaq y ha solicitado una audiencia ante el Nasdaq Hearings Panel; actualmente sus acciones están suspendidas en Nasdaq.
El CEO Steven Lo enfatizó el compromiso de la empresa para avanzar en el desarrollo de su vacuna oral en pastilla, considerando todas las opciones respecto a la cotización de sus acciones. Los accionistas no necesitan tomar ninguna acción respecto a esta transición de mercado.
Vaxart (OTCQX: VXRT)는 경구용 재조합 알약 백신을 개발하는 임상 단계의 바이오테크 기업으로, 2025년 7월 8일부터 OTCQX Best Market으로 거래 이전을 발표했습니다. 회사는 나스닥으로부터 상장폐지 통보를 받았으며, 나스닥 청문회 패널 앞에서 심리를 요청한 상태로 현재 주식은 나스닥 거래가 중단된 상태입니다.
CEO 스티븐 로는 자사 독자적인 경구용 알약 백신 개발을 추진하는 데 집중하고 있으며, 주식 상장 관련 모든 옵션을 검토 중임을 강조했습니다. 주주들은 이번 거래 이전과 관련해 별도의 조치를 취할 필요가 없습니다.
Vaxart (OTCQX : VXRT), une société de biotechnologie en phase clinique développant des vaccins recombinants oraux sous forme de pilules, a annoncé sa transition vers la cotation sur le marché OTCQX Best Market à compter du 8 juillet 2025. L'entreprise a reçu un avis de radiation de la Nasdaq et a demandé une audience devant le Nasdaq Hearings Panel ; son action est actuellement suspendue du trading sur Nasdaq.
Le PDG Steven Lo a souligné l'engagement de la société à faire progresser le développement de son vaccin oral en pilule tout en examinant toutes les options concernant la cotation de ses actions. Les actionnaires n'ont aucune démarche à effectuer concernant cette transition de marché.
Vaxart (OTCQX: VXRT), ein biotechnologisches Unternehmen in der klinischen Phase, das orale rekombinante Pillenimpfstoffe entwickelt, gab seinen Übergang zum OTCQX Best Market mit Wirkung zum 8. Juli 2025 bekannt. Das Unternehmen erhielt eine Delisting-Mitteilung von der Nasdaq und hat eine Anhörung vor dem Nasdaq Hearings Panel beantragt; die Aktie ist derzeit vom Nasdaq-Handel ausgesetzt.
CEO Steven Lo betonte das Engagement des Unternehmens, die Entwicklung ihres proprietären oralen Pillenimpfstoffs voranzutreiben und dabei alle Optionen bezüglich der Börsennotierung zu prüfen. Aktionäre müssen im Zusammenhang mit diesem Handelsübergang keine Maßnahmen ergreifen.
- Trading on OTCQX Best Market provides maximum transparency and visibility in OTC Markets
- Company continues development of innovative oral pill vaccine platform
- No action required from shareholders for trading transition
- Received delisting notice from Nasdaq
- Stock currently suspended from Nasdaq trading
- Downgrade from Nasdaq to OTCQX market may reduce institutional investor access
SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its common stock has been approved to trade on the OTCQX® Best Market. The Company’s shares will commence trading at the open of the market on July 8, 2025, under its existing ticker symbol “VXRT.” Shareholders will not need to take any action. The OTCQX Market, being the highest tier of OTC Markets Group, enables Vaxart to provide the greatest transparency, visibility, and accessibility to investors available in the OTC Markets.
In addition, after receiving a delisting notice from Nasdaq, Vaxart has requested a hearing before a Nasdaq Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), Vaxart’s common stock remains suspended pending a decision from the Nasdaq Hearings Panel.
“We are considering all options regarding our stock listing, keeping our shareholders best interests in mind. At the same time, our focus will remain on strengthening Vaxart by advancing the development of our proprietary oral pill vaccines, which are engineered to address infectious diseases,” said Steven Lo, Chief Executive Officer of Vaxart.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Forward-Looking Statements
Statements contained or incorporated by reference in this press release which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, meetings, and potential collaborations are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date of this press release. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, consequences of the Delisting Notice, results of the Company’s appeal to the Hearings Panel, the Company’s ability to regain compliance with the Minimum Bid Price Requirement, the Company’s continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.
Contact
| Vaxart Media and Investor Relations: |
| Matt Steinberg |
| FINN Partners |
| IR@vaxart.com |
| (646) 871-8481 |
This press release was published by a CLEAR® Verified individual.
FAQ
Why is Vaxart (VXRT) moving to OTCQX from Nasdaq?
What happens to Vaxart (VXRT) shareholders after the move to OTCQX?
Is Vaxart (VXRT) completely delisted from Nasdaq?
What is Vaxart's (VXRT) main business focus during this transition?
What is the OTCQX Best Market where Vaxart (VXRT) will trade?
